MTOR and autosomal dominant polycystic kidney disease: Analysis from a two-year randomized controlled trial, CRAD001ADE12, suggests that the accelerated growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD) can be slowed down with the use of everolimus, a mammalian target of rapamycin (mTOR) inhibitor (57).